US top court to hear case on gene patents

by Jean-Louis Santini

The US Supreme Court will hear arguments Monday on whether to allow private entities to patent genes they have isolated and identified, a decision that could have far-reaching implications for genetic research.

The nine justices will review a 2012 appeals court decision that allowed a , Myriad Genetics Inc, to patent two it found had links to breast and .

But the ruling has drawn protest from a broad group, including associations representing some 150,000 researchers, doctors and patients, who are now asking the nation's top court to overturn it.

"Our is based on 150 years Supreme court doctrine that says, under the patent act, products and are not patentable," said lawyer Sandra Park of the , which is leading the judicial battle along with the Patent .

According to Park, extracting a gene from a cell to isolate it does not constitute an invention by itself.

"Myriad did not invent either of those qualities, just as a doctor that removes a kidney from the body for transplant does not somehow invent that kidney," she said.

"Obstacle" to research

For Joseph Stiglitz, a Nobel laureate in economics who teaches at Columbia University in New York, Myriad's two patents obtained in the 1990s create a "lack of access to testing but also a lack of access for further development of basic research."

Park explained that "because of Myriad's patent of the gene, no other scientists can look at these genes."

The "very broad" patent "precludes any laboratory or scientists from doing clinical or research work with theses genes because isolation is fundamental to doing anything with them," she emphasized.

As a result, the researchers are unable to develop competing tests that may potentially be more effective than Myriad's to determine if a women is a carrier of the mutations that predispose her to breast or ovarian cancer.

That's a crucial problem, said Ellen Matloff, director of cancer genetic counseling at the Yale Cancer Center, because Myriad's test falls short and fails to detect the mutated genes in some women.

"No one else can do testing, no one else can offer a more comprehensive test and unfortunately as a result of that, that will cost lives," Matloff lamented.

Moreover, with its monopoly, Myriad can bill more than $3,000 for an analysis that, Matloff said, should cost a tenth as much.

But Myriad defends its patents and denies they cover mere products of nature.

"Myriad created synthetic molecules of DNA in the laboratory that are used to test patients for increased risk of breast cancer and ovarian cancer," the company said in a statement.

"Those synthetic molecules are different from what is found in nature or the human body," it emphasized.

It maintained, as well, that the discovery of the two genes, the product of research that typically requires years of effort and large investments, ought to be protected.

Nearly 20 percent of the approximately 24,000 human genes are currently under , some of which are associated with Alzheimer's disease or other cancers.

These patents are sometimes owned by private companies but also by universities and research institutes concerned with keeping them in the public domain to prevent companies from seizing them.

The Supreme Court's decision is expected in June.

add to favorites email to friend print save as pdf

Related Stories

US court to decide if human genes can be patented

Nov 30, 2012

The Supreme Court announced Friday it will decide whether companies can patent human genes, a decision that could reshape medical research in the United States and the fight against diseases like breast and ovarian cancer.

High court throws out human gene patents

Mar 26, 2012

(AP) -- The Supreme Court on Monday threw out a lower court ruling allowing human genes to be patented, a topic of enormous interest to cancer researchers, patients and drug makers.

Myriad can patent breast cancer genes: US court

Jul 30, 2011

A federal appeals court on Friday ruled in favor of Myriad Genetics after a legal battle over whether the US company could keep its patent on genes linked to an inherited form of breast cancer.

Recommended for you

A nucleotide change could initiate fragile X syndrome

39 minutes ago

Researchers reveal how the alteration of a single nucleotide—the basic building block of DNA—could initiate fragile X syndrome, the most common inherited form of intellectual disability. The study appears ...

Gene clues to glaucoma risk

21 hours ago

Scientists on Sunday said they had identified six genetic variants linked to glaucoma, a discovery that should help earlier diagnosis and better treatment for this often-debilitating eye disease.

Mutation disables innate immune system

Aug 29, 2014

A Ludwig Maximilian University of Munich team has shown that defects in the JAGN1 gene inhibit the function of a specific type of white blood cells, and account for a rare congenital immune deficiency that ...

Study identifies genetic change in autism-related gene

Aug 28, 2014

A new study from Bradley Hospital has identified a genetic change in a recently identified autism-associated gene, which may provide further insight into the causes of autism. The study, now published online in the Journal of ...

NIH issues finalized policy on genomic data sharing

Aug 27, 2014

The National Institutes of Health has issued a final NIH Genomic Data Sharing (GDS) policy to promote data sharing as a way to speed the translation of data into knowledge, products and procedures that improve health while ...

User comments